Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for SCYNEXIS's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:135 vs IXHL, ETST, INIS: Total Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS Total Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (FRA:135) has a Total Payout Ratio of 3.92 as of Aug. 16, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Total Payout Ratio too high?
SCYNEXIS's current Total Payout Ratio is 3.92. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Total Payout Ratio compare to IXHL and ETST?
SCYNEXIS's Total Payout Ratio of 3.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Drug Manufacturers company?
A good Total Payout Ratio depends on the Drug Manufacturers industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Total Payout Ratio is 3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Total Payout Ratio of 3.92. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Total Payout Ratio is 3.92. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Total Payout Ratio is 3.92 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (FRA:135) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.
Key valuation signals for FRA:135:
Total Payout Ratio: 3.92
GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score
Get the complete analysis for FRA:135
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:135 has been successfully added to your 
